News >

Long-Term and Brain Mets Data Demonstrate Strong Dabrafenib/Trametinib Efficacy in Melanoma

Gina Columbus @ginacolumbusonc
Published: Sunday, Jul 09, 2017

Jeffrey S. Weber, MD, PhD

Jeffrey S. Weber, MD, PhD

Favorable long-term phase II results of the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF V600-mutant melanoma were presented at the 2017 ASCO Annual Meeting, demonstrating that the regimen had 4-year and 5-year overall survival (OS) rates of 30% and 28%, respectively.1

during the 2017 ASCO Annual Meeting.

OncLive: Can you discuss the 5-year follow-up results with the dabrafenib/trametinib combination in melanoma presented at the 2017 ASCO Annual Meeting?

Weber: The gist of the presentation that I made was that our study was the longest-term follow-up with any BRAF/MEK inhibitory combination trial done. This was a randomized phase II portion of a larger phase I/II trial, part C, in which 50 or so patients per arm were randomized to get the BRAF/MEK inhibitor combination, dabrafenib/trametinib, at the standard dose of dabrafenib 150 mg twice daily by mouth and then trametinib at either 2 mg or 1 mg once daily by mouth versus the control arm of dabrafenib alone, which was then an FDA-approved treatment at the 150-mg daily standard dose.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication